Drug Profile
IGN 301
Alternative Names: SDZ-MMA-383Latest Information Update: 05 Nov 2009
Price :
$50
*
At a glance
- Originator Novartis; Sandoz
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 05 Nov 2009 Discontinued - Phase-I for Cancer in Austria (SC)
- 05 Nov 2009 Discontinued - Phase-I for Cancer in Europe (SC)
- 05 Nov 2009 Discontinued - Phase-I for Cancer in USA (SC)